Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 14 studies | 22% ± 9% | |
lung | 9 studies | 28% ± 10% | |
brain | 7 studies | 31% ± 11% | |
intestine | 5 studies | 25% ± 11% | |
kidney | 4 studies | 19% ± 4% | |
uterus | 4 studies | 24% ± 11% | |
bone marrow | 3 studies | 21% ± 5% | |
breast | 3 studies | 19% ± 1% | |
adipose | 3 studies | 17% ± 2% | |
liver | 3 studies | 31% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 4557.10 | 459 / 459 | 100% | 48.43 | 1118 / 1118 |
intestine | 100% | 3941.60 | 966 / 966 | 100% | 35.90 | 527 / 527 |
ovary | 100% | 3266.47 | 180 / 180 | 100% | 33.19 | 430 / 430 |
stomach | 100% | 2656.10 | 359 / 359 | 100% | 33.75 | 286 / 286 |
uterus | 100% | 4028.38 | 170 / 170 | 100% | 49.23 | 459 / 459 |
esophagus | 100% | 5276.64 | 1444 / 1445 | 100% | 43.85 | 183 / 183 |
lung | 100% | 3935.40 | 577 / 578 | 100% | 38.72 | 1155 / 1155 |
bladder | 100% | 3916.95 | 21 / 21 | 100% | 42.56 | 503 / 504 |
prostate | 100% | 3223.38 | 244 / 245 | 100% | 32.58 | 501 / 502 |
thymus | 100% | 3051.07 | 652 / 653 | 99% | 26.01 | 601 / 605 |
skin | 100% | 7983.03 | 1809 / 1809 | 99% | 37.36 | 468 / 472 |
brain | 99% | 2160.00 | 2610 / 2642 | 100% | 36.78 | 705 / 705 |
liver | 100% | 2286.31 | 226 / 226 | 99% | 20.80 | 401 / 406 |
pancreas | 98% | 2096.88 | 322 / 328 | 99% | 35.21 | 177 / 178 |
kidney | 100% | 3033.54 | 89 / 89 | 96% | 29.19 | 869 / 901 |
adrenal gland | 100% | 3313.57 | 258 / 258 | 94% | 17.31 | 216 / 230 |
adipose | 100% | 5250.95 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 4311.97 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 33.13 | 29 / 29 |
spleen | 100% | 4120.15 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 51.52 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 18.62 | 1 / 1 |
peripheral blood | 99% | 6551.99 | 921 / 929 | 0% | 0 | 0 / 0 |
heart | 93% | 1677.73 | 799 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 90% | 16.69 | 72 / 80 |
muscle | 80% | 1034.21 | 645 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007194 | Biological process | negative regulation of adenylate cyclase activity |
GO_0007188 | Biological process | adenylate cyclase-modulating G protein-coupled receptor signaling pathway |
GO_0046039 | Biological process | GTP metabolic process |
GO_0051301 | Biological process | cell division |
GO_0007193 | Biological process | adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway |
GO_0016239 | Biological process | positive regulation of macroautophagy |
GO_0007212 | Biological process | G protein-coupled dopamine receptor signaling pathway |
GO_0005730 | Cellular component | nucleolus |
GO_0030496 | Cellular component | midbody |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005813 | Cellular component | centrosome |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0000139 | Cellular component | Golgi membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0005834 | Cellular component | heterotrimeric G-protein complex |
GO_0005765 | Cellular component | lysosomal membrane |
GO_0019003 | Molecular function | GDP binding |
GO_0031683 | Molecular function | G-protein beta/gamma-subunit complex binding |
GO_0001664 | Molecular function | G protein-coupled receptor binding |
GO_0005525 | Molecular function | GTP binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0005515 | Molecular function | protein binding |
GO_0003924 | Molecular function | GTPase activity |
Gene name | GNAI3 |
Protein name | Guanine nucleotide-binding protein G(i) subunit alpha-3 (G(i) alpha-3) |
Synonyms | |
Description | FUNCTION: Heterotrimeric guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signaling cascades. The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state. Signaling by an activated GPCR promotes GDP release and GTP binding. The alpha subunit has a low GTPase activity that converts bound GTP to GDP, thereby terminating the signal. Both GDP release and GTP hydrolysis are modulated by numerous regulatory proteins . Signaling is mediated via effector proteins, such as adenylate cyclase. Inhibits adenylate cyclase activity, leading to decreased intracellular cAMP levels . Stimulates the activity of receptor-regulated K(+) channels . The active GTP-bound form prevents the association of RGS14 with centrosomes and is required for the translocation of RGS14 from the cytoplasm to the plasma membrane. May play a role in cell division . . |
Accessions | P08754 ENST00000369851.7 |